Some of ongoing combination therapy trials with erlotinib are: NCT01294306 - erlotinib and AKT inhibitor MK2206; NCT01859026 - erlotinib and MEK inhibitor MEK162, in EGFR and KRAS mutant NSCLC; NCT00994123 – erlotinib and MM-121, an anti-ERBB3 antibody (see below, under ERBB3 section), NCT01454102 – erlotinib and nivolumab (anti-PD-1 antibody), NCT00966472 - erlotinib with Rosurastatin, NCT01186861 - erlotinib and linsitinib/OSI-906 (IGF1R inhibitor); NCT01708954 - erlotinib with Aurora A inhibitor MLN8237; NCT01471964 – erlotinib and mTOR ihnibitor CC-223. This evidence concerns the gene EGFR and non-small cell lung carcinoma.